Transplant Trial Watch

Marine n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Kidney Transplant Recipients: A Randomized, Placebo-Controlled Trial.

Jorgensen, H. S., et al

Nutrients 2021; 13(7): 10.

The aim of this study was to examine the effects of marine n-3 polyunsaturated fatty acids (n-3 PUFA) supplementation on bone mass density (BMD) and mineral metabolism in renal transplant patients.

Participants were randomised to either the 2.6 g marine n-3 PUFA supplement (intervention) group or the olive oil (control) group.

132 adult kidney transplant patients.

The main outcomes included changes in BMD and biochemical parameters including plasma intact parathyroid hormone (iPTH), 25-hydroxy vitamin D, phosphate, and total and ionized calcium.

44 weeks

CET Conclusions
The secondary endpoint analysis of the double-blind, randomised controlled trial (ORENTRA) investigated the effect of a marine n-3 polyunsaturated fatty acids (n-3 PUFA) supplement on bone mass and mineral metabolism in kidney transplant recipients. Adult recipients were randomly allocated to receive n-3 PUFA or a matching placebo (olive oil) from weeks 8 to 52 posttransplant. The primary endpoint analysis was previously published and showed that n-3 PUFA did not improve renal function when compared with placebo (Eide IA, et al. AJT 2019; 19: 790-800). The secondary endpoints were analysed in both the intention-to-treat (ITT) and per-protocol (PP) populations. Both analyses did not find any statistically significant differences between groups for bone mineral density (whole body, lumbar spine, proximal femur and the non-dominant forearm) or for any of the biochemical markers of calcium metabolism.

Trial registration - NCT01744067

Funding source
Industry & non-industry funded